MedPath

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

• Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children's Health Ireland, marking the first evaluation in a pediatric patient. • The clinical assessment is led by Dr. Alan Irvine, a leading dermatologist, aiming to broaden the data set for QRX003 and potentially lower the eligibility age for treatment. • QRX003 is currently in late-stage clinical trials with promising data showing improvement across multiple endpoints and no treatment-related adverse events in older patients. • Quoin plans to expand the clinical assessment to include additional pediatric subjects in Spain and has opened or plans to open clinical sites in the US, Saudi Arabia, and the UK.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has commenced clinical testing of its lead product, QRX003, in a young child diagnosed with Netherton Syndrome (NS). This rare, inherited genetic disorder currently lacks an approved treatment or cure, making this a significant step forward.
The clinical assessment is being conducted at Children's Health Ireland in Dublin, under the guidance of Dr. Alan Irvine, a consultant dermatologist and professor at Trinity College Dublin. Dr. Irvine's extensive experience in epithelial genetics and his role as president of the International Eczema Council position him as a key figure in this evaluation.

Clinical Significance and Expansion

Dr. Michael Myers, CEO of Quoin, emphasized the importance of this initiative, stating, "We are pleased to announce this latest initiative for Quoin as we strive to generate the broadest and most diverse data set possible for QRX003 in Netherton Syndrome patients." The company hopes that the data from this assessment will support lowering the eligibility age for QRX003 treatment. Plans are underway to broaden the clinical assessment to include three additional pediatric subjects in Spain.

QRX003: A Potential Treatment for Netherton Syndrome

QRX003 is Quoin's most advanced product in development and is currently being evaluated in two late-stage clinical trials. The trials are being conducted under an open Investigational New Drug application with the U.S. Food and Drug Administration. To date, clinical data has been promising, with all evaluable subjects showing improvement across a number of endpoints and no treatment-related adverse events recorded. In addition to the five open clinical sites in the United States, a sixth site is opening in Saudi Arabia, and two additional clinical sites are planned to open in the United Kingdom.

About Netherton Syndrome and QRX003

Netherton Syndrome is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene, leading to severe skin barrier defects, recurring infections, and a predisposition to allergies, asthma, and eczema. Patients often suffer from severe dehydration, chronic skin inflammation, and stunted growth. QRX003 is a topical lotion formulated with a proprietary delivery technology containing a broad-spectrum serine protease inhibitor, designed to normalize skin-shedding and strengthen the skin barrier by performing the function of the LEKTI protein, which is absent in Netherton patients.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Quoin Pharmaceuticals' QRX003 Shows Promise in Netherton Syndrome Trial

Quoin Pharmaceuticals' QRX003 demonstrates significant symptom reduction in a Netherton Syndrome clinical trial, with an 83% improvement observed in the first subject after 12 weeks.
The open-label study showed improvements across multiple clinical endpoints, including M-IASI, WINRS, and IGA, with no reported safety concerns and high patient satisfaction.

Quoin Pharmaceuticals Expands QRX003 Clinical Program for Netherton Syndrome and Peeling Skin Syndrome

Quoin Pharmaceuticals is assessing QRX003 in a pediatric patient with Netherton Syndrome (NS), addressing the need for early treatment in this rare genetic disease.
The company is expanding its clinical activities internationally, with new sites in Saudi Arabia and the UK, to accelerate recruitment and diversify the patient population.

Quoin Pharmaceuticals Advances QRX003 for Rare Skin Disorders, Expands Clinical Trials

Quoin Pharmaceuticals initiates an investigator-led clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome, a condition with no approved treatments.
The company is expanding its Netherton Syndrome clinical program internationally, opening two additional sites in the United Kingdom.

Quoin Pharmaceuticals Advances QRX003 Clinical Programs for Rare Skin Diseases

Quoin Pharmaceuticals initiates a clinical study in New Zealand for QRX003 targeting Peeling Skin Syndrome, a condition with no approved treatments.
The company expands its Netherton Syndrome clinical trials by adding two new sites in the United Kingdom, enhancing international reach.

Grunenthal's Qutenza Phase III Trial Completes Enrollment for Post-Surgical Neuropathic Pain

Grunenthal and Averitas Pharma completed enrollment for the Phase III clinical trial AV001, evaluating Qutenza in post-surgical neuropathic pain (PSNP).
The trial aims to assess the efficacy, safety, and tolerability of Qutenza (capsaicin) 8% topical system for PSNP, a condition affecting over 3 million people in the U.S. annually.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland in Dublin.
This assessment marks the first evaluation of QRX003 in a pediatric patient, with plans to expand the study to include additional pediatric subjects in Spain.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome, a rare genetic disease with no approved treatments.
The clinical assessment is led by Dr. Alan Irvine, a leading dermatology researcher, aiming to broaden QRX003's data set in younger patients.

Quoin Pharmaceuticals Initiates Clinical Testing of QRX003 in Pediatric Netherton Syndrome Patient

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a young child with Netherton Syndrome at Children’s Health Ireland, marking the first evaluation of the drug in a pediatric patient.
The clinical assessment is led by Dr. Alan Irvine, a leading researcher in Netherton Syndrome, aiming to broaden the data set for QRX003 and potentially lower the eligibility age for treatment.

Quoin Pharmaceuticals Initiates Pediatric Trial of QRX003 for Netherton Syndrome

Quoin Pharmaceuticals has begun clinical testing of QRX003 in a pediatric patient with Netherton Syndrome in Dublin.
The company plans to expand the trial to include three additional pediatric patients in Spain.

Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Trials to the UK

Quoin Pharmaceuticals expands its Netherton Syndrome (NS) clinical trials to include two new sites in the United Kingdom.
The clinical sites are Great Ormond Street Hospital and St. Thomas’ Hospital, both recognized for Netherton Syndrome treatment.

Reference News

[1]
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton ...
manilatimes.net · Nov 5, 2024

Quoin Pharmaceuticals initiates testing of QRX003 for Netherton Syndrome in a pediatric patient at Children's Health Ire...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy